


available at www.sciencedirect.comwww.elsevier.com/locate/jprot

Comparative analysis of synovial fluid and plasma proteomes in juvenile arthritis – Proteomic patterns of joint inflammation in early stage disease

David S. Gibson^{a,*}, Sarah Blelock^a, Jim Curry^a, Sorcha Finnegan^a,
Adrienne Healy^a, Caitriona Scaife^b, Catherine McAllister^a,
Stephen Pennington^b, Michael Dunn^b, Madeleine Rooney^a

^aArthritis Research Group, Musculoskeletal Research Unit, Queen's University Belfast, Belfast, United Kingdom

^bProteome Research Centre, UCD Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland

ARTICLE DATA

Article history:

Received 20 November 2008

Accepted 9 January 2009

Keywords:

Synovial fluid

Proteomics

Inflammation

Juvenile arthritis

ABSTRACT

Synovial fluid is a potential source of novel biomarkers for many arthritic disorders involving joint inflammation, including juvenile idiopathic arthritis. We first compared the distinctive protein 'fingerprints' of local inflammation in synovial fluid with systemic profiles within matched plasma samples. The synovial fluid proteome at the time of joint inflammation was then evaluated across clinical subgroups to identify early disease associated proteins. We measured the synovial fluid and plasma proteomes using the two-dimensional fluorescence difference gel electrophoresis approach. Image analysis software was used to highlight the expression levels of joint and subgroup associated proteins across the study cohort ($n=32$). A defined subset of 30 proteins had statistically significant differences ($p<0.05$) between sample types such that synovial fluid could be differentiated from plasma. Furthermore distinctive synovial proteome expression patterns segregate patient subgroups. Protein expression patterns localized in the chronically inflamed joint therefore have the potential to identify patients more likely to suffer disease which will spread from a single joint to multiple joints. The proteins identified could act as criteria to prevent disease extension by more aggressive therapeutic intervention directed at an earlier stage than is currently possible.

Crown Copyright © 2009 Published by Elsevier B.V. All rights reserved.

1. Introduction

Around one in every thousand children in the UK suffers from juvenile idiopathic arthritis (JIA) [1]. The worldwide reported incidence varies on a geographical basis, from 0.7 per 1000 in USA to 4.0 per 1000 in Australia [2]. JIA is a heterogeneous group of inflammatory disorders primarily affecting the musculoskeletal system. The most common symptoms of JIA are persistent joint swelling, pain and stiffness. JIA

normally affects the load bearing joints of the knee and foot, with movement limited by pain [3]. Adverse outcomes can present to varying degrees regardless of disease subtype, but persistently inflamed joints are a major risk factor [4]. The main outcomes include limitation of joint function, joint structural damage due to erosions and in severe cases disability or death. JIA subtypes vary considerably in the pattern and severity of joint inflammation, disease progression and outcome.

* Corresponding author. Arthritis Research Group, Queen's University Belfast, Whitla Medical Building (3rd Floor), 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom. Tel.: +44 2890 902877; fax: +44 2890 661112.

E-mail address: d.gibson@qub.ac.uk (D.S. Gibson).

Typically, the course of all subtypes of JIA is one of exacerbations and remissions. However, some may have one or two “flare ups” and never have symptoms again, while others experience repeated “flare ups” or disease that is persistently active into adulthood.

JIA targets the lining of the joint, the synovial membrane, causing inflammation or synovitis [5]. When synovitis persists joint damage may occur. Tissue destruction results from a dysregulation at the molecular level between synthesis and breakdown of the matrix components of joint cartilage [6].

In oligoarticular disease, children are managed with NSAIDs and intra-articular steroid injections to relieve pain and inflammation, slow down or prevent the joint destruction and restore joint function. To effectively manage and minimize the effects of recurrent synovitis however, an early and accurate diagnosis is essential [7]. Successful clinical management can be induced in most (54%) JIA patients with polyarticular disease, using combined anti-inflammatory treatment (NSAID and Methotrexate MTX) [8]. Even so, nearly half the patients will have relapses after treatment is discontinued. The rate of relapses may be influenced by residual synovial inflammation at the time when immunosuppressive treatment is withdrawn. Once the disease is in clinical remission, it is important to know when it is possible to withdraw immunosuppressive drugs, without inducing a flare because of their potentially serious side effects [9]. For a clinician there are three main concerns: maintaining disease remission, prevention and pre-empting disease spread and ultimately averting permanent joint damage and disability. If there was a predictive test that would allow disease progression to be forecast and therefore modify treatment accordingly, significant benefit could be provided to patients.

Although the main clinical manifestation of arthritis is destructive joint inflammation, many other organs may be targeted by the inflammatory process. A holistic view inclusive of local and systemic aspects of the disease is more likely to achieve satisfactory disease resolution. We postulate that biomarkers may exist, which can make a distinction between local and systemic protein expression patterns across the disease subtypes.

To date, there are no means of identifying those apparently clinically inactive patients at special risk of relapse. The current definition of disease activity in JIA is exclusively based on clinical or routine laboratory measures. Consequently, a large proportion of patients may be diagnosed at a relatively advanced stage of the disease, restricting the clinician’s ability to modify disease outcome and reducing the efficacy of therapeutic intervention [10].

Traditional acute phase response markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) show no significant difference between responders and non-responders to steroids [11]. Even in early disease histopathological study of JIA synovial membranes indicate that patients diagnosed with JIA, exhibit increased vascularity, B and T cell infiltrates and hyperplasia [12]. All these features are evidence of an advanced stage in the inflammatory process. Since samples within the current study are from newly diagnosed patients (<6 months), we have the potential opportunity to characterize early stage disease.

Work on the proteome of arthritic biological fluids and tissue is in its infancy, with little information available on

juvenile disease. It was therefore essential that we undertook preliminary work to demonstrate the power and sensitivity of proteomics to study differentially expressed proteins in fluids from JIA. Our pilot study uncovered fragments of extracellular matrix and T-cell receptor proteins, products of the degradative proteolytic environs of the recurrently inflamed knee [13]. These peptides were observed as indicators of two processes which are likely to be partly interlinked-hypertrophic cartilage breakdown and T-cell infiltration [14].

The predictors and mechanisms of arthritic disease have focused on areas such as T cells, cytokines, fibroblasts, proteases or osteoclasts. What is clear though, is that no single agent or process is wholly responsible, but rather the interaction of these processes resulting in a characteristic protein expression pattern with a particular inflammatory nature. Proteomics is therefore an ideal systems biology approach to examine the multifaceted processes at work in arthritis [15]. In addition multiplex diagnostics are more likely to reflect the true complexity of the arthritis disease process. Fluorescence difference gel electrophoresis (DIGE) was applied in this study as the spectrally distinct Cy dye fluorophores permit multiplexing of corresponding synovial fluid and plasma from an individual patient. The inclusion of an internal pooled standard (composed of all experiment samples), on each gel allows proteome comparisons to be made between patients and biological variation between body fluids to be reliably quantified.

It is reasonable to propose that the most efficient biomarkers for diagnosing or classifying inflammation will be localized within the affected joints. On the other hand it is equally important to assess the systemic molecular foundations of the disease, which may not be clinically apparent. From a practicality viewpoint it is also preferable to be able to quantify biomarkers in plasma as it is more easily accessed with less trauma to children in particular, who may suffer repeated bouts of joint inflammation. The plasma proteome is not only composed of haemostatic proteins confined to the vascular system but also transient secretions of proteins from tissues as a part of normal developmental/aging processes or disease. The proteomic profile of plasma therefore encodes the physiological state of the tissues it is circulated around. However many authors caution that the most meaningful diagnostic plasma proteins are also likely to be found at the lowest abundance, since they are released from tissue into the blood with temporal and spatial restrictions [16]. Moving further upstream of plasma to a biofluid proximal to the disease site is therefore likely to be more fruitful in the initial phases of biomarker candidate discovery.

This study is concerned with revealing protein markers to allow us to not only track the process of inflammation in detail, but more importantly to dissecting out synovial protein expression patterns which may identify more reliable predictors of JIA outcome. We initially performed a study of the proteins expressed within synovial fluid and plasma in early JIA in order to discover novel biomarkers which distinguish between local and systemic components of joint inflammation in arthritis. A subsequent comparison of the synovial proteome across patient subgroups provided evidence that such analysis could be of potential use in patient stratification or even prognosis.

2. Methods

2.1. Patients

Thirty two patients with juvenile idiopathic arthritis (JIA) according to ILAR criteria entered this study. At the time of initial sampling there were 18 children with oligo-articular arthritis and 11 with RF-ve poly-articular arthritis. After a year, 8 oligo-articular had extended disease, with more affected joints than originally assessed, and were therefore reclassified as extended oligo-articular patients. This patient cohort was split into two study groups for proteome comparisons of: (A) synovial fluid versus plasma ($n=10$), and (B) JIA subgroups ($n=22$). See Table 1 for patient demographics of each study group.

All patients were examined by a consultant rheumatologist, (MR), who confirmed their diagnosis. For the purposes of this study, only initial synovial fluids from children with a disease duration of less than six months were studied.

Intra-articular steroid (Triamcinolone acetonide) injections of the knee were performed with ultrasound guidance, under general anaesthetic, with the dose determined by the size of the joint. (Triamcinolone hexacetonide was not available during the time of this study). Clinical details recorded included subtype of JIA, age, sex, disease duration, local and general disease activity and where appropriate -time to local recurrence, ESR and CRP. Local inflammation was defined as both joint swelling and pain on physical examination.

All synovial fluids (SF) were aspirated using an aseptic technique and plasma obtained at the same procedure. The SF and plasma samples were immediately centrifuged at 5000 g for 15 min at 4 °C to remove any particulate or cellular material, aliquoted and stored at -80 °C until analyzed. Medical Ethics Committee approval was obtained for this study at Green Park Healthcare Trust and patient assent and parent informed consent given.

2.2. Sample preparation

Proteins within patient fluids were extracted and stabilized for 1 h at 4 °C by addition of M-PER[®] protein extraction reagent

(Pierce Biotechnology Inc., Rockford, USA) and a protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany). Samples were subsequently dialyzed overnight at 4 °C in distilled water to remove salts, with 3.5 kDa cut-off membrane Slide-A-Lyzer[®] cassettes (Pierce Biotechnology Inc., Rockford, USA). Each purified patient fluid was snap frozen in liquid nitrogen and lyophilized over night under vacuum on a Christ freeze dryer (Martin Christ GmbH, Osterode am Harz, Germany). Matched synovial fluid and plasma samples were re-hydrated in sample re-hydration buffer (8 M Urea, 2% CHAPS and 0.002% bromophenol blue) (Invitrogen Ltd., Paisley, UK), with gentle agitation to prevent foaming. Protein concentrations were measured using the PlusOne[™] 2-D Quant kit according to manufacturer's guidelines (GE Healthcare, Bucks, UK).

2.3. Difference in gel electrophoresis

Electrophoresis was performed with a Ettan[™] IPGphor II IEF System, an Ettan[™] DALTwelve Large Vertical System and associated power supply, strips, gels and reagents according to the manufacturer's guidelines (GE Healthcare, Bucks, UK). 50 μ g of each synovial fluid and plasma sample were minimally labeled with Cy5 and Cy3 fluorescent dyes according to the manufacturer's recommendations of cross-labelling. An internal pooled standard was generated by combining equal amounts of all matched synovial fluid and plasma samples, followed by Cy2 dye labelling. Equal amounts (50 μ g) of Cy5 and Cy3 samples and Cy2 standard were combined and resuspended in an equal volume of 2 \times sample buffer (8 M Urea, 130 mM DTT, 4% (w/v) CHAPS, 2% (v/v) Pharmalyte[™] 4–7). Rehydration buffer (8 M Urea, 13 mM DTT, 4% (w/v) CHAPS, 1% (v/v) Pharmalyte[™] 4–7) was added to make up the volume to 450 ml prior to IEF. Each sample was applied to a 24 cm Immobiline DryStrip pH 4–7 linear immobilized pH gradient (IPG) strip and re-hydrated overnight. Previous runs with pH 3–10 carrier ampholytes and IPG strips revealed most of the proteins focused within the pH 4–7 range [15]. The first dimension separation of proteins by isoelectric focusing (IEF) was performed for a total of 75,000 Vh (2 mA/5 W limit per strip) including a final 8000 V step for 1 h to obtain high quality resolution.

Table 1 – Clinical and demographic characteristics of the study subjects.

Experiment / comparison	(A) Body fluid (synovial fluid vs plasma)				(B) Patient subgroup (oligo vs extended oligo vs poly)			
	Oligo	Extended oligo	Poly	Total	Oligo	Extended oligo	Poly	Total
Patient subgroup								
Number	3	3	4	10	10	5	7	22
Age (years)	7.2 \pm 0.56	7.1 \pm 4.75	6.1 \pm 2.78	6.7 \pm 2.83	7.8 \pm 4.15	6.0 \pm 3.69	5.1 \pm 2.31	6.6 \pm 3.60
Male / female (n)	2/1	0/3	1/3	3/7	5/5	0/5	1/6	6/16
Duration of JIA (weeks)	9.6 \pm 7.43	12.0 \pm 9.00	5.6 \pm 2.70	8.7 \pm 6.38	7.0 \pm 6.50	11.8 \pm 7.6	8.7 \pm 6.06	8.7 \pm 6.57
No. Of swollen joints (n)	1.3 \pm 0.58	3.7 \pm 0.58	4.5 \pm 0.58	3.3 \pm 1.49	1.7 \pm 0.82	4.0 \pm 0.71	4.0 \pm 1.63	3.0 \pm 1.59
Serum CRP (mg/l)	8.1 \pm 2.76	6.3 \pm 1.84	17.8 \pm 16.79	11.5 \pm 11.27	7.5 \pm 1.60	7.1 \pm 2.11	13.6 \pm 13.14	9.4 \pm 7.75
ESR (mm/h)	10.0 \pm 10.39	7.3 \pm 3.06	60.3 \pm 32.27	29.3 \pm 32.92	10.7 \pm 7.15	9.8 \pm 4.02	50.3 \pm 31.63	23.1 \pm 25.93
NSAID (yes/no)	3/0	2/1	3/1	8/2	8/2	4/1	6/11	8/4
DMARD (yes/no)	0/3	0/3	0/4	0/10	0/10	2/3	0/7	2/20
Biologic (yes/no)	0/3	0/3	1/3	1/9	0/10	0/5	1/6	1/21

Values are the mean \pm standard deviation or the number of subjects. Subgroups descriptors: Oligo=oligoarticular 4 joints or less involved at diagnosis; Poly=polyarticular, 5 joints or more involved at diagnosis; Extended Oligo=patients who become polyarticular 6 months after diagnosis. CRP=C-reactive protein; ESR=erythrocyte sedimentation rate. All study patients were rheumatoid factor negative.

After IEF, the strips were equilibrated in equilibration for two 15 minute steps with gentle rocking in 6 M urea, 50 mM Tris pH8.8, 30% (v/v) Glycerol, 2% (w/v) SDS. In the first equilibration step 1% (w/v) dithiothreitol was added as a reducing agent and in the second 2.5% (w/v) iodoacetamide included to reduce protein streaking by alkylation. Post-equilibration, IPG strips were laid into single well 12% PAGE gels (26 × 20 cm; 1 mm thick) and sealed in with 1% agarose (w/v) in running buffer (25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS and bromophenol blue). The second dimension separation was run at 0.75 W/gel, with temperature control for 19 h, until the bromophenol blue dye front had reached the end of the gel. Two preparative pick gels (to isolate proteins for identification) were loaded with 500 mg of unlabelled protein consisting of an equal amount of each sample. These preparative gels were stained with silver and colloidal Coomassie blue for MALDI-TOF and nESI-MS/MS, respectively.

2.4. Image analysis

Prelabeled proteins were visualized using a Typhoon™ 9410 imager (GE Healthcare, Bucks, UK). The Cy5 images were scanned using a 633 nm laser and a 670 nm band pass (bp) filter; Cy3 images were scanned using a 532 nm laser and a 580 nm bp filter; Cy2 images were scanned using a 488 nm laser and an emission filter of 520 nm. All gels were scanned at 100 nm pixel resolution. The photomultiplier tube was set so pixel intensity remained between 35,000 and 65,000 for any given Cy dye.

Gel analysis was performed with Progenesis Samespots version 2.0 build 2644.18003 (Nonlinear Dynamics Ltd. Newcastle upon Tyne, UK.), software comprising gel warping, DIGE normalization and comparison modules. Briefly a single reference gel was assigned to the gel image with the most spots detected and all remaining gel images were aligned to this reference. The same spot outlines were overlaid onto all images ensuring no data was omitted at this early stage. Landmark spots were used to confirm spot matching across all gels and manual verification of characteristic three-dimensional 'peaks' was used to screen out any dust artifacts or incorrectly identified spots. The protein spots in each image were automatically linked between the three Cy dye images per gel. The Cy2 spot intensities (volume) were used to normalize the Cy3 and Cy5 spot volumes. The normalized volume (NV) for each spot on each gel was calculated by the software from the ratio of the volume of the Cy3 (or Cy5) labeled sample to that of the Cy2 labelled internal standard. The progenesis software performs log transformation of the spot volume ratios to generate normally distributed data. Log normalized volume (LNV) was used in quantifying differential expression.

Spots were matched across replicate sample sets and normalized spot volumes were used to create master gels for experimental comparison. For example in study group A ten gel images were combined to create one SF and one plasma 'master' gel. Subsequent qualitative subtraction of plasma from matched synovial fluid 'master' gels revealed a population of proteins uniquely over-expressed in the joint. Quantitative differential spot analysis was performed on 'master' gels from both of the experimental groups. Pairwise comparisons were made to establish synovial fluid-to-plasma, inter-

subgroup, inter-patient and Cy3-to-Cy5 dye variations. Within the Samespots review module each comparison was filtered to find the spots (a) with a p value ≤ 0.05 for the paired t -test, (b) having a greater than two-fold change in expression between the groups, and (c) being correctly matched in at least six of the patients. Fold change was calculated as the ratio of the average LNV between study groups.

2.5. Cluster analysis

Quantitative data sets were exported to Excel spread sheet and analysed using Eplust (<http://www.bioinf.ebc.ee/EP/EP/EPCLUST/>), a generic data clustering, visualization, and analysis tool for genomic or proteomic expression data. Hierarchical analysis allows samples with inter-individual protein expression patterns that are highly similar to be reordered in an agglomerative fashion, using the unweighted pair-group average (UPGMA) clustering procedure. In this method, the distance between two clusters is calculated as the average distance between all pairs of objects in the two different clusters. Euclidean distance was the similarity measure used to group or separate the expression data. The grouping of protein expression levels is presented in the form of heatmap accompanied by dendrograms with trees and branches depicting the extent of similarity between the different groups in the samples.

2.6. Mass spectrometry identification and verification

Protein spots were excised from silver-stained 2D gels and digested by use of the protocol described by [17]. Briefly, the gel spots were washed with 50 mmol/L NH_4HCO_3 /acetonitrile (1:1), followed by dehydration with acetonitrile. The proteins were reduced in 10 mmol/L dithiothreitol/50 mmol/L NH_4HCO_3 for 1 h at 56 °C and alkylated in 55 mmol/L iodoacetamide/50 mmol/L NH_4HCO_3 for 2 h at room temperature. The gel pieces were washed several times in 50 mmol/L NH_4HCO_3 , followed by dehydration with acetonitrile. The proteins were digested overnight with trypsin (Promega, modified trypsin) at 37 °C, and the resulting peptide mixtures were analyzed by MALDI-TOF mass fingerprint and/or MALDI-TOF/TOF peptide sequencing at Alphalyse A/S (Odense, Denmark). The instrument used was a MALDI-TOF/TOF Autoflex III from Bruker Daltonics (Bremen, Germany). Mass spectra were acquired in the 500–3000 m/z scan range. The mass accuracy was calibrated to within 50 ppm using calibration standards (standard peptide calibration mix from Bruker Daltonics) before each run. The peaklist was generated with Bruker Daltonics Flexanalysis 3.0 software using the Sophisticated Numerical Annotation Procedure (SNAP) algorithm, a signal to noise ratio of >3 , a quality factor of 20 and median baseline subtraction. The peptide masses obtained were used to query the non-redundant sequence database (NRDB-NCBI 2007.07.06) for protein identification using the Mascot database search program version 2.10.03. A list of excluded contaminant ions and species restriction was not used. The NRDB database contains 4,655,816 entries and is maintained and updated by the European Molecular Biology Laboratory. Database search parameters considered: (i) that the trypsin enzyme cleaves on the C-terminal side of KR unless next

residue is P, (ii) no fixed modifications, (iii) carbamidomethyl cysteine and oxidation methionine variable modifications, (iv) up to 1 missed cleavage permitted with no fixed modifications (v) peptide tolerance set at 60 ppm for the precursor ions and (vi) 0.7 Da mass tolerance for the fragment ions. The acceptance criteria for PMF based identifications was a minimum Mascot score of 50, using a 95% confidence interval threshold ($p < 0.05$). The peptide ions identified in this study by MALDI-TOF and further CID MS/MS analysis independently matched to single protein entries in the database.

Protein identifications were independently verified at Queen's University Belfast by nano-electrospray-ionization (nESI-MS/MS) from a similar Coomassie colloidal blue stained gel. Digested peptides were extracted in 5% trifluoroacetic acid, 50% acetonitrile in ultrapure water with sonication for 6 min. After a gel pellet was formed by brief centrifugation, the supernatant was desalted using a C18 ZipTip (Pierce Biotechnology Inc., Rockford, USA) and dehydrated in SC 210A Speed Vac vacuum evaporator (Savant Instruments Inc., Hicksville, USA). Desalted peptide digests were subjected to nESI-MS/MS with a LCQ Deca ion trap-mass spectrometer (ThermoFinnigan, San Jose, USA), operated with dynamic exclusion via LCQ Tune software (version 1.1). MS/MS data was recorded over a 400–2000 m/z scan range, with positive polarity and 35 kV collision energy. MS/MS data was collected by Xcalibur (version 1.1) and integrated using the Interactive Chemical Information System (ICIS) peak detection algorithm software provided by Finnigan

as default. MS/MS ion search was performed by Mascot search engine (version 2.10.03) (Matrix Science Inc., Boston, USA), using the database NCBI nr (2007.05.12) containing 4,914,404 sequences. The following are the standard search parameters: (i) trypsin cleavage, (ii) no fixed modifications, (iii) no constraints on protein mass or mass value, (iv) peptide and MS/MS tolerances set at 1.2 and 0.6 Da, respectively and (v) peptide charge was set at 2+ and up to 1 missed cleavage permitted. Mascot used the Mowse scoring algorithm [18]. A threshold score of >49 indicates that the identity is significant if it would be expected to occur at random with a frequency of less than 5%.

3. Results

3.1. Universal proteome expression patterns across sample types

The simultaneous analysis of individual paired plasma and synovial fluids from ten patients (Table 1, study group A) was used to initially isolate joint-specific protein expression profiles, without introducing bias from inter-individual differences. Pilot 2-DE gels revealed that the majority of proteins from the sampled fluids migrated to within the pH 4–7 range (results not shown). A characteristic pattern of protein migration is apparent in the 2-DE gel scans of both synovial fluid and plasma samples (see Fig. 1). A number of high abundance proteins form

MWt (KDa)




Fig. 1 – DIGE reveals ~900 spots per gel within the pH 4–7 range for synovial fluid. Spot filtering on ‘master gels’ reveals 143 protein spots which predominate in synovial fluid or plasma. Attention was focussed on a series of 26 synovial fluid proteins (circled in red) and 26 plasma proteins (circled in blue) as these spots remained unmatched or were expressed at a two-fold or higher level than could be detected in the corresponding fluid. Interestingly, the synovial fluid ‘specific’ proteins were all under ~60 KDa, whereas the plasma ‘specific’ had a wider molecular weight range from ~10 to 200 KDa. All 30 proteins spots were cut from replicate preparative gels and MALDI-TOF and nESI-MS/MS was used to ascertain their identity. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

a series of typical charge trains. This spread of proteins is consistent with previous work by other laboratories and our own [13,19]. Interesting distinctions are revealed between the local (synovial fluid, SF) and systemic (plasma) molecular signatures of juvenile arthritis subgroups. On initial visual inspection it is apparent that as one of the predominant sets of high molecular weight proteins present in blood, fibrinogen is principally retained within blood.

Approximately 900 spots per synovial fluid gel image and 800 spots per plasma gel image were automatically detected and matched across patients by Samespots software analysis. The upper and lower limits of detection for the Cy dye stained body fluids spanned 5 orders of magnitude. Protein spots were uniquely numbered by synchronization to those in a reference gel. Intensity differences in spots matched between synovial and plasma master gels were quantified and normalized to the internal standard allowing real comparisons of individual protein spots from both sample types across the patient cohort. A master gel was constructed for each sample type with the gel analysis software and spot filtering performed to highlight spots which predominate in synovial fluid and those which predominate in plasma. Spots which predominate in the SF/PL could be presumed to originate in either fluid and were described as SF/PL 'specific'.

3.2. Differential protein expression between synovial fluid and plasma

A number of proteins with consistent synovial and plasma 'specific' expression patterns are highlighted and quantified to demonstrate the ability to reliably differentiate molecular fingerprints of local and systemic disease across patient groups

by this gel based approach. A spot filtering rationale to narrow our focus on the most prevalent and most consistent patterns was applied across the ten patients expression data set. Images of areas from master gels (see Fig. 2) demonstrate the inter-sample variation in the expression of 'synovial specific' proteins (spots 23, 29, 36, 25) in synovial fluids and absence in plasma samples. A series of 26 synovial fluid proteins and 26 plasma proteins were selected on the basis that they were expressed at a two-fold or higher levels than could be detected within the corresponding fluid. The inter-individual and inter-sample type variation in these 52 proteins is represented in heatmap form in Fig. 4.

Even though many of the protein constituents of synovial fluid are derived from plasma, some appear to be enriched in synovial fluid borne out by the higher synovial fluid to plasma ratios (listed in Table 2). Though an approximate 200 fold dynamic range is apparent between the highest and lowest SF/PL ratios listed, we found the top and bottom detection range was over 5 orders of magnitude. Interestingly, the synovial fluid 'specific' proteins were all under ~55 KDa, whereas the plasma 'specific' had a wider molecular weight range from ~10 to 200 KDa (as indicated in Fig. 1). The statistical significance of a protein differing in abundance between the two sample types in one or more individuals is indicated by the p values listed in Table 2.

3.3. Variation in protein expression across individuals

We found that there is a degree of proteome variability across individual patient body fluid samples. To date, no results have been published on the variability of the synovial fluid proteome analysed by the DIGE method. Statistical analysis of inter-patient variance revealed that 18 synovial 'specific' and 12 plasma 'specific' spots within the previously described




Fig. 2 – Images of areas from master gels demonstrate the expression of 'synovial specific' proteins (A- spots 23, 25, 29, 36) in synovial fluids and 'plasma specific' expression (B- spots 2, 4, 9, 10). Subsequent qualitative subtraction of plasma from matched synovial fluid 'master' gels revealed a population of proteins uniquely expressed in the joint in JIA patients.

Table 2 – Protein name, mass spectrometry data, fold differences between fluids and variation across patients are compiled for the 31 plasma and synovial fluid associated proteins.

Spot no.	SF/ PL ratio	% CV SF	% CV PL	Paired t-test (p)	Protein name	Accession number	MW (kDa)	Mascot score	Sequence coverage (%)	Matched peptide	Verification CID ions
1	0.034	115.99%	34.88%	9.49E-12	Transthyretin, Chain B	55669576	12.8	434	92	10	4
2	0.035	66.60%	44.35%	1.71E-12	Serum albumin	23307793	69.3	298	22	15	5
3	0.036	66.12%	32.90%	9.63E-13	Serum albumin	23307793	69.3	409	42	23	6
4	0.039	68.88%	33.37%	2.11E-12	Serum albumin	62113341	69.0	148	26	6	2
5	0.041	76.91%	36.07%	8.45E-12	Serum albumin	28592	69.3	253	30	24	4
6	0.046	46.28%	42.52%	2.00E-13	Serum albumin	62113341	69.0	337	37	28	5
9	0.101	91.01%	43.33%	3.56E-08	ALB protein	27692693	47.3	309	40	19	4
10	0.107	41.59%	47.05%	1.59E-10	Serum albumin	62113341	69.0	205	32	25	4
16	0.150	29.82%	23.59%	2.50E-12	Albumin precursor PRO2619	11493459	56.7	199	14	7	3
28	0.264	23.72%	41.29%	5.26E-08	ALB protein	27692693	47.3	342	46	20	4
81	0.440	54.20%	34.66%	6.74E-04	No ID	–	–	–	–	–	–
86	0.445	31.90%	31.59%	2.05E-05	Transferrin chain A	49258810	36.1	68	23	9	2
11	7.451	122.81%	41.81%	6.58E-04	Apolipoprotein A-I, Chain C,	90108666	28.0	277	51	16	3
13	7.072	125.23%	59.58%	5.08E-04	Serum Albumin	62113341	69.0	93	12	22	3
14	7.071	172.69%	46.96%	1.74E-03	No ID	–	–	–	–	–	–
23	4.745	57.71%	34.73%	6.33E-06	Albumin precursor PRO2619	11493459	56.7	200	29	16	4
25	4.359	58.40%	29.20%	6.78E-06	Apolipoprotein C-III precursor	4557323	10.8	99	19	2	1
29	3.714	51.16%	37.14%	1.37E-05	Albumin precursor PRO2619	11493459	56.7	185	31	16	5
31	3.621	53.77%	38.91%	1.97E-05	Albumin precursor PRO1851	7770149	70.9	163	17	12	3
36	3.291	52.65%	17.68%	3.95E-06	ALB Protein	27692693	47.3	177	33	16	2
37	3.274	51.10%	51.41%	2.15E-05	No ID	–	–	–	–	–	–
42	3.005	57.12%	33.04%	1.16E-04	Alpha-1 antitrypsin	28637	22.8	162	50	14	4
49	2.884	33.28%	31.85%	2.06E-06	Properdin, B-factor	257209925	85.4	165	17	12	3
53	2.763	92.05%	33.54%	4.51E-03	Apolipoprotein A-II	119573006	9.0	69	27	3	1
56	2.647	82.35%	31.78%	1.00E-03	No ID	–	–	–	–	–	–
57	2.631	89.56%	32.31%	1.12E-02	Apolipoprotein A-I, Chain A	90108664	28.1	100	30	9	1
65	2.393	62.69%	30.35%	8.72E-04	Albumin	119626069	13.8	44	23	3	1
73	2.341	59.48%	39.11%	7.84E-03	Alpha-1 antitrypsin, Chain	1942629	44.2	217	22	9	2
99	2.115	67.65%	59.09%	2.76E-02	Alpha-1 antitrypsin, Chain	1942953	44.3	56	17	6	1
104	2.077	18.06%	32.48%	8.90E-06	Serum albumin	62113341	69.0	136	26	19	3

Spot trypsin digests were initially identified using matrix assisted laser desorption ionisation (MALDI-TOF) and confirmed with nano-electrospray mass spectra (nESI-MS/MS), correlated to compiled peptide data (Matrixscience). The number of matching peptide and collision induced dissociation (CID) ions used to verify protein identity are listed alongside sequence coverage and Mascot score. Mascot used the Mowse scoring algorithm [17]. This indicates that the identity is significant if it would be expected to occur at random with a frequency of less than 5%. A positive control spot picked from the 2-DE gel molecular weight markers was correctly identified as myoglobin. Peptide ion sequence and peak lists can be found in Table 3.




Fig. 3 – Pairwise comparisons were made to establish patient-to-patient, synovial fluid-to-plasma and Cy3-to-Cy5 dye variations. Statistical analysis of inter-patient variance revealed that 19 synovial ‘specific’ and 12 plasma ‘specific’ spots within this subgroup of proteins were consistently expressed in all patients studied ($p < 0.05$). The expression levels of properdin (spot 49) are visible in a section of gel images from individual patient (1–10) synovial fluid (A) and plasma (B) samples. The log normalized peak volume of properdin is plotted for each patient sample shown (C), such that the first ten points represent synovial fluid levels and the latter ten points represent plasma levels.

subgroup of 52 proteins were consistently expressed in all patients studied. Representative images of areas from individual gels (see Fig. 3) demonstrate the inter-individual variation in the expression of a representative ‘synovial specific’ protein (spot 49) in synovial fluids and its absence in corresponding plasma samples.

We calculated the expression variance of a selected group of 30 proteins (standard deviation / mean, expressed in percent) and observed that standard deviations can be high across the synovial samples in particular (e.g. proteins 11, 14, 53). A disparity is evident between synovial fluid and plasma in the degree of variation for given protein (e.g.

proteins 56, 57). Generally speaking, for a given protein, detected levels in synovial fluid vary on a wider scale (~30–70% on average) than those in plasma (~30–50% on average). Exceptions to this rule are evident, where the standard deviation for certain proteins (6, 16, 37 and 49) across the 10 patients is closely matched for both sample types.

3.4. Cluster analysis and protein identification of a defined synovial fluid proteome (study group A)

The normalised expression data from the pool of 52 proteins, previously selected due their two fold abundance in one fluid




Fig. 4 – The inter-individual and inter-sample type variation in 52 pre-selected proteins is represented in heatmap form and reordered by hierarchical cluster analysis revealing distinguishing expression patterns. Each patient sample is represented by a single numbered column; plasma (PI, blue) and synovial fluid (Sy, red). 30 of the proteins consistently overexpressed at twofold higher levels than in the corresponding fluid are highlighted (by *). The location of spots from the comparative heatmap is shown in Fig. 1. Observed arbitrary clusters of co-regulated proteins (C1 and C2) fluid ‘specific’ expression patterns (C3 and C4) are indicated. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

type, were subjected to hierarchical cluster analysis to visualize their expression characteristics across each patient fluid (see Fig. 4). The clustering algorithm applied distinguishes plasma and synovial fluid, forming two clear blocks of plasma and synovial fluid abundant proteins in the top and bottom halves, respectively. Groups of co-regulated proteins can be rapidly identified by their absence or presence pattern as demonstrated by clusters labeled C1 and C2. Certain groups of patients seem to form smaller clusters, whereby a fluid ‘specific’ expression pattern is apparent, synovial fluid clusters are apparent in regions labeled C3 and C4. The agglomerative nature of clustering reorders the data such that the degree of similarity between patients is strongest for proteins listed at the top and weakest at the bottom. This is represented by the constructed dendrogram, whereby the shortest arms signify the expression levels are closest. It is interesting therefore to note that the selected plasma proteome produces the most consistent expression patterns.

30 proteins selected on their ability to distinguish one fluid from another, were cut from replicate silver stained preparative gels and mass spectrometry was used to ascertain their identity. Protein name, mass spectrometry data, fold differences between fluids and variation across patients are compiled for these proteins in Table 2. Detailed information on each identification including peptide ion sequence identified is included in Table 3.

Albumin isoforms were common to both fluids, but even so, some unique expression traits were evident in this class of ubiquitous blood proteins. Certain isoforms were detected exclusively in plasma (gi23307793 and gi28592) or synovial fluid (gi119626069). Other albumin species detected in both plasma and synovial fluid could be distinguished by their molecular weights (ascertained from 2-DE gel images), such that isoforms (gi62113341, gi11493459, gi27692693) of the same albumin species above 55 KDa were predominant in plasma and those below 55 KDa were more abundant in synovial fluid. For example the albumin gi11493459 (PRO2619) was identified from the three separate gel cores of spots 16, 23 and 29, positioned at approximate molecular weights of 60, 48 and 47 KDa respectively (Fig. 1). The two lower molecular weight forms are more abundant in synovial fluid, with 4.7 and 3.7 fold more, respectively. Conversely, transthyretin and transferrin chain fragments were identified at 29.4 and 2.2 fold higher levels in plasma, respectively.

Several apolipoprotein species were amongst those proteins commonly over expressed in synovial fluid. A disproportionate synovial abundance of chain C from apolipoprotein A-1 compared to chain A from the same molecule is evident from the SF/PI ratios. Apolipoproteins A-II and C-III precursor were also detected at significantly higher levels in synovial fluid. Two isoforms of alpha-1 antitrypsin (gi28637 and gi1942629) were detected with molecular weight estimates ranging from 45–54 KDa (spots 42, 73 and 99) according to gel markers.

Table 3 – Peptide ion validation data from CID MS/MS mass spectrometry which corresponds with Table 2.

Spot no.	Protein name	Accession number	Verification CID ions	Peptide position in protein sequence: start–end	m/z	Ions score	Amino acid sequence	Variable modification: carbamidomethyl cysteine (C), oxidation methionine (M)
1	Transthyretin, Chain B	55669576	4	12–24	1366.74	89	R.GSPAINVAVHVFR.K	
				12–25	1494.84	75	R.GSPAINVAVHVFRK.A	
				25–38	1522.70	88	R.KAADDTWEPFASGK.T	
				26–38	1394.60	47	K.AADDTWEPFASGK.T	
2	Serum albumin	23307793	5	299–310	1546.80	25	K.LKECCEKPLLEK.S	2C
				361–372	1467.85	51	R.RHPDYSVLLLLR.L	
				362–372	1311.76	18	R.HPDYSVLLLLR.L	
				438–452	1639.94	97	K.KVPQVSTPTLVEVSR.N	
3	Serum albumin	23307793	6	439–452	1511.85	62	K.VPQVSTPTLVEVSR.N	
				35–44	1226.60	57	R.FKDLGEENFK.A	
				123–138	1996.92	57	R.NECFLQHKDDNPPLR.L	C
				162–168	927.49	47	K.YLYEIAR.R	
4	Serum albumin	62113341	2	361–372	1467.83	57	R.RHPDYSVLLLLR.L	
				427–434	960.56	44	K.FQNALLVR.Y	
				438–452	1639.92	13	K.KVPQVSTPTLVEVSR.N	
				570–581	1342.63	79	K.AVMDDFAAFVEK.C	
5	Serum albumin	28592	4	570–581	1358.62	79	K.AVMDDFAAFVEK.C	M
				162–168	927.51	19	K.YLYEIAR.R	
				361–372	1467.84	19	R.RHPDYSVLLLLR.L	
				427–434	960.58	33	K.FQNALLVR.Y	
6	Serum albumin	62113341	5	438–452	1639.94	54	K.KVPQVSTPTLVEVSR.N	
				162–168	927.49	39	K.YLYEIAR.R	
				162–169	1083.59	19	K.YLYEIARR.H	
				234–242	1019.58	37	R.AFKAWAVAR.L	
9	ALB protein	27692693	4	427–434	960.56	45	K.FQNALLVR.Y	
				438–452	1639.93	76	K.KVPQVSTPTLVEVSR.N	
				107–118	1546.79	37	K.LKECCEKPLLEK.S	2C
				169–180	1467.84	32	R.RHPDYSVLLLLR.L	
10	Serum albumin	62113341	4	235–242	960.57	39	K.FQNALLVR.Y	
				246–260	1639.95	82	K.KVPQVSTPTLVEVSR.N	
				162–168	927.51	42	K.YLYEIAR.R	
				162–169	1083.61	18	K.YLYEIARR.H	
16	Albumin precursor PRO2619	11493459	3	234–242	1019.6	14	R.AFKAWAVAR.L	
				427–434	960.58	26	K.FQNALLVR.Y	
				399–414	1910.94	41	R.RPCFSALEVDETYVVK.E	C
				440–448	1000.60	41	K.QTALVELVK.H	
28	ALB protein	27692693	4	460–471	1358.62	90	K.AVMDDFAAFVEK.C	M
				169–180	1467.82	54	R.RHPDYSVLLLLR.L	
				235–242	960.55	49	K.FQNALLVR.Y	
				246–260	1639.92	93	K.KVPQVSTPTLVEVSR.N	
81	No ID	–	–	247–260	1511.83	53	K.VPQVSTPTLVEVSR.N	
				42–50	1125.61	4	K.KASYLDCIR.A	C
				43–50	997.52	23	K.ASYLDCIR.A	C
				24–40	1815.86	48	K.DSGRDYVSQFEGSALGK.Q	
11	Apolipoprotein A-I, Chain C,	90108666	3	119–131	1467.81	22	K.VEPLRAELQEGAR.Q	
				161–171	1301.66	28	R.THLAPYSDEL.R.Q	
				162–168	927.51	25	K.YLYEIAR.R	
13	Serum albumin	62113341	3	162–169	1083.61	9	K.YLYEIARR.H	
				427–434	960.58	22	K.FQNALLVR.Y	
				251–262	1467.85	23	R.RHPDYSVLLLLR.L	
23	Albumin precursor PRO2619	11493459	4	317–324	960.58	30	K.FQNALLVR.Y	
				328–342	1639.94	69	K.KVPQVSTPTLVEVSR.N	
				399–414	1910.94	7	R.RPCFSALEVDETYVVK.E	C
				45–60	1716.84	79	K.DALSSVQESQVAQAR.G	
25	Apolipoprotein C-III precursor	4557323	1	251–262	1467.84	20	R.RHPDYSVLLLLR.L	
				317–324	960.57	26	K.FQNALLVR.Y	
29	Albumin precursor PRO2619	11493459	5					

(continued on next page)

Table 3 (continued)

Spot no.	Protein name	Accession number	Verification CID ions	Peptide position in protein sequence: start–end	m/z	Ions score	Amino acid sequence	Variable modification: carbamidomethyl cysteine (C), oxidation methionine (M)
31	Albumin precursor PRO1851	7770149	3	328–342	1639.94	64	K.KVPQVSTPTLVEVSR.N	C
				329–342	1511.85	7	K.VPQVSTPTLVEVSR.N	
				399–414	1910.94	3	R.RPCFSALEVDETYVVK.E	
				468–489	2415.14	73	R.QGPNVLLSDPEQGVVEVT GQYER.E	
				468–491	2672.28	50	R.QGPNVLLSDPEQGVVEVTGQ YEREK.A	
36	ALB Protein	27692693	2	610–622	1454.73	5	R.TLRVQGNDSATRE	
				235–242	960.58	28	K.FQNALLVR.Y	
				246–260	1639.97	67	K.KVPQVSTPTLVEVSR.N	
37	No ID	–	–					
42	Alpha-1 antitrypsin	28637	4	75–84	1275.71	7	K.GKWERPFEVK.D	
				106–116	1403.72	12	K.RLGMFNIQHCK.K	
				107–116	1247.61	41	R.LGMFNIQHCK.K	
				158–165	1078.55	26	K.FLENEDRR.S	
49	Properdin, B-factor	57209925	3	51–74	2815.37	33	R.LLQEGQALEYVCPSPGFYPYP VQTR.T	C
				177–193	2056.94	28	K.VGSQYRLEDSVTYHCSR.G	
				183–193	1366.61	66	R.LEDSVTYHCSR.G	
53	Apolipoprotein A-II	119573006	1	48–57	1156.68	38	K.SKEQLTPLIK.K	
56	No ID	–	–					
57	Apolipoprotein A-I, Chain A	90108664	1	1–10	1226.56	27	DEPPQSPWDR.V	
65	Albumin	119626069	1	66–75	1149.65	20	K.LVNEVTEFAK.T	
73	Alpha-1 antitrypsin, chain	1942629	2	11–25	1779.75	60	K.TDTSHHDDHPTFNK.I	
				156–168	1479.73	95	K.QINDYVEKGTQGK.I	
99	Alpha-1 antitrypsin, Chain	1942953	1	11–25	1779.77	24	K.TDTSHHDDHPTFNK.I	
104	Serum albumin	62113341	3	66–75	1149.63	33	K.LVNEVTEFAK.T	
				162–169	1083.61	8	K.YLYEIARR.H	
				438–452	1639.97	23	K.KVPQVSTPTLVEVSR.N	
344	No ID	–	–					

Peptide position in the matched protein, observed mass (m/z) and amino acid sequence are listed for each protein match found.

Furthermore, inter alpha trypsin inhibitor and properdin were identified among those proteins enriched within synovial fluid. A number of proteins remained unidentified, probably attributable to a low protein yield from gel cores.

3.5. Cluster analysis differentiates proteins which segregate patient subgroups (study group B)

A 'master' gel was constructed for each patient subgroup with the image analysis software and spot filtering performed to highlight spots which predominate in a particular subgroup. Attention was focussed on a series of 40 synovial fluid proteins (circled and labelled in Fig. 5A) as these spots were expressed at a two-fold or higher level in pairwise comparisons of the other patient subgroups with statistical significance by ANOVA ($p < 0.05$). The group of selected synovial fluid proteins fell within ~10 to 100 kDa molecular weight range. Certain proteins predominate in two patient subgroups e.g. proteins 37 and 892 abundant in both the polyarticular and extended oligoarticular patient subgroups, whereas others apparently predominate in a single subgroup e.g. proteins 5 and 907 in polyarticular or protein 865 in oligoarticular

patients (highlighted in Fig. 5B). Multivariate analysis was subsequently used to visualize inter-patient and inter-subgroup expression patterns of the 40 selected protein spots.

The highlighted proteome was further explored by hierarchical cluster analysis of the 40 selected proteins and visualization in heat map form (Fig. 6). Pearson ranked correlation revealed three distinctive clusters. Cluster 1 contains proteins which are consistently over expressed in both extended oligoarticular and polyarticular patients, whereas proteins in cluster 2 predominate only in the polyarticular subgroup. Intriguingly, proteins in cluster 3 are consistently overexpressed in the oligoarticular and polyarticular subgroups relative to those patients with disease extension. It seems conceivable that used in combination these three distinct clusters within the synovial fluid proteome could be used to differentiate disease subgroups. The unpaired *t*-test revealed proteins with significant fluctuations between combinations of any two patient subgroups. The *p* values are summarized in Table 4. Having established the significance of protein expression patterns it was pertinent to assign identities using mass spectrometry.




Fig. 5 – Fluorescence difference in gel electrophoresis (DIGE) of synovial fluid (A). A series of 40 synovial fluid proteins, encircled and numbered above, were expressed at a two-fold or higher level than could be detected in the other two patient subgroups with statistical significance by ANOVA ($p < 0.05$). Representative protein expression patterns in synovial fluid are shown in selected areas of ‘master’ gels (B) (37, 41, 892, 5, 566, 907, 542, 865, 947). The colours (red, green, blue) used to encircle spots and spot numbers correlate to the clusters observed in the data after hierarchical cluster analysis, shown in Fig. 5. 40 proteins spots were cut from replicate preparative gels and MALDI-TOF and nESI-MS/MS was used to ascertain their identity. Representative DIGE separation of plasma is also highlighted (C). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 6 – Hierarchical cluster analysis of proteins expressed with statistically significant differences between patient subgroups. The inter-individual and inter-group variation in 40 pre-selected proteins is represented in heatmap form. The protein expression data was reordered by hierarchical cluster analysis (HCA) using Pearson centred correlation (UPGMA), revealing distinguishing expression patterns. 3 main clusters of the proteins are highlighted by the coloured bars (red, green blue). Each patient sample is represented by a single numbered column (oligoarticular O1–O9, extended oligoarticular EO1–EO5 and polyarticular P1–P7). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

3.6. Discriminatory SF proteome identification and inter-subgroup variation (study group B)

The mass spectrometry derived identification and inter-subgroup variation of the 40 selected proteins are listed in Table 4. Detailed information on each identification including peptide ion sequence identified is included in Table 5. In order to highlight proteins which may discriminate disease extension, emphasis was placed on statistically significant correlations to extended oligoarticular patients. As the most ubiquitous protein, six albumin isoforms (*a*, *g*, *h*, *k*, *p* and *t*) were identified as 11 distinct protein spots from picking gels and were distributed throughout the 3 identified protein clusters, predominating in cluster 1. Within cluster 3, albumin isoforms *t* and *k* were over expressed 4.8 ($p=0.049$), 2.9 ($p=0.018$) and 3.0 ($p=0.038$) fold in extended oligoarticular patients when compared to the oligoarticular subgroup, whereas albumin isoforms *a* and *g* are conversely underexpressed 2.7 ($p=0.021$) and 6.9 ($p=0.021$) fold, respectively, in patients with disease extension. Intriguingly, albumin complexed with the non-steroidal anti-inflammatory drug (NSAID) S-naproxen (spot numbers 41 and 904) was detected at significantly raised levels in extended oligoarticular contrasted with oligoarticular patients with similar 2.4 ($p=0.006$) and 2.3 fold ($p=0.045$) differences recorded for isoforms isolated from two distinct protein spots.

Apolipoproteins AI and AII were significantly overexpressed 2.9 ($p=0.008$) and 2.6 ($p=0.046$) fold, respectively, in polyarticular patients when contrasted against oligoarticular and extended oligoarticular subgroups. In clusters 1 and 3, transferrin was identified as two independent protein spots (42,33) representing

non-glycosylated and N-lobe forms of chain A. Levels of the non-glycosylated transferrin were raised 2.0 ($p=0.014$) fold in patients who showed disease extension, whereas the transferrin N-lobe displayed the inverse with 2.6 ($p=0.045$) fold less, relative to oligoarticular patients. Complement component C3c and hemo-pexin display analogous overexpression in polyarticular patients when balanced alongside oligoarticular and extended oligoarticular subgroups. Interestingly, from the point of view of JIA pathology vitamin D binding protein was detected in polyarticular patients at significantly overexpressed levels, 2.2 ($p=0.019$) fold, when compared to oligoarticular patients in cluster 1.

In addition, several spots (18, 542 and 699) were identified as Immunoglobulin (Ig) fragments within cluster 3 at significantly reduced levels in the patients with disease extension to oligoarticular patients. Ig heavy chain variable region, IgK1 and Ig light chains were under expressed 5.4 ($p=0.030$), 3.0 ($p=0.023$) and 2.9 ($p=0.020$) fold in the extended oligoarticular subgroup relative to the oligoarticular subgroup. Ig heavy chain variable region was concomitantly overexpressed 3.3 ($p=0.032$) fold in the polyarticular patients when compared to the extended subgroup. A number of protein spots remained unidentified, attributable to low protein yield from the gel core extraction process.

4. Discussion

Proteins and peptides actively or passively secreted and shed from the synovial membrane accumulate in synovial fluid. Potential biomarkers could therefore be enriched within this fluid relative to plasma. In the first study (group A) we have

Table 4 – Protein name, mass spectrometry data, fold differences between subgroups and their statistical significance are compiled for 40 synovial fluid associated proteins.

Spot ID	Normalised spot volume – mean (SD)			Inter-group comparison – fold difference, unpaired t-test ($p < 0.05$)						Mass Spectrometry spectrometry data – MALDI-TOF/TOF							
	Oligo	Ext oligo	Poly	O vs EO	<i>p</i>	O vs P	<i>p</i>	EO vs P	<i>p</i>	Protein name	Accession number	<i>pI</i>	MW (KDa)	Mascot score	Sequence coverage	Matched peptides	Verification CID ions
20	41.89 (36.27)	201.65 (148.45)	151.27 (151.74)	4.8	0.049	3.6	0.086	-1.3	0.547	Albumin, isoform CRA-t	119626083	6.66	58614	53	5	3	2
26	260.05 (236.07)	266.79 (190.06)	1001.18 (668.96)	1.0	0.953	3.8	0.017	3.8	0.018	Leucine -rich alpha-2-glycoprotein 1	16418467	6.45	38154	189	23	7	2
27	193.16 (118.20)	492.74 (375.05)	725.81 (430.15)	2.6	0.115	3.8	0.011	1.5	0.311	HP protein	47124562	8.48	31362	80	28	8	3
32	26.56 (31.24)	76.19 (45.75)	55.12 (37.80)	2.9	0.018	2.1	0.089	-1.4	0.364	Albumin, isoform CRA-k	119626074	5.97	47257	130	24	11	3
37	329.60 (379.47)	566.12 (290.03)	841.30 (654.40)	1.7	0.206	2.6	0.046	1.5	0.359	Apolipoprotein A-II isoform CRA_c	119573006	6.15	8958	108	32	4	1
39	179.67 (179.91)	429.56 (301.20)	381.20 (193.98)	2.4	0.047	2.1	0.032	-1.1	0.721	No identification	~	~	~	~	~	~	~
41	722.35 (584.88)	1700.28(614.83)	1641.77 (1240.87)	2.4	0.006	2.3	0.084	-1.0	0.918	Serum Albumin with S-Naproxen, Chain A	168988718	5.63	65778	322	32	25	8
42	17.59 (8.62)	34.368 (16.56)	39.75 (24.79)	2.0	0.014	2.3	0.042	1.2	0.655	Apo-serum transferrin (non-glycosylated), Chain A	110590597	6.58	74643	377	38	26	8
43	69.84 (70.74)	96.93 (47.48)	153.98 (68.75)	1.4	0.417	2.2	0.019	1.6	0.108	Vitamin D-binding protein/group specific component	455970	5.34	52916	205	9	7	5
694	141.51 (107.45)	459.84 (408.33)	512.87 (396.27)	3.2	0.120	3.6	0.036	1.1	0.811	Albumin, isoform CRA_h	119626071	5.92	68568	75	17	9	3
769	179.08 (237.44)	540.87 (424.53)	521.11 (518.79)	3.0	0.038	2.9	0.116	-1.0	0.941	Albumin, isoform CRA_k	119626074	5.97	47257	255	32	15	4
770	292.30 (262.61)	218.54 (112.10)	658.83 (464.93)	-1.3	0.526	2.3	0.043	3.0	0.033	No Identification	~	~	~	~	~	~	~
872	263.68 (207.60)	635.23 (386.92)	645.72 (414.37)	2.4	0.020	2.4	0.040	1.0	0.962	HP Protein	47124562	8.48	31362	218	40	13	3
892	66.05 (57.56)	152.32 (114.73)	154.37 (109.81)	2.3	0.054	2.3	0.035	1.0	0.974	Albumin, isoform CRA_h	119626071	5.92	68568	225	19	12	5
900	279.14 (251.24)	509.13 (407.48)	640.99 (462.64)	1.8	0.167	2.3	0.042	1.3	0.590	Haptoglobin	3337390	6.14	38209	232	31	14	3
904	43.29 (40.48)	98.89 (65.47)	59.66 (54.74)	2.3	0.045	1.4	0.463	-1.7	0.245	Serum Albumin with S-Naproxen, Chain A	168988718	5.63	65778	340	23	16	7
5	2618.22 (4761.74)	349.76 (558.22)	6111.70 (6599.47)	-7.5	0.150	2.3	0.196	17.5	0.044	Albumin, isoform CRA_h	119626071	5.92	68568	168	22	17	4
24	498.13 (550.89)	407.73 (366.73)	1743.37 (1484.23)	-1.2	0.725	3.5	0.054	4.3	0.040	Haptoglobin	3337390	6.14	38209	191	33	14	3
25	1015.31 (912.91)	1130.96 (645.34)	4293.33 (3251.87)	1.1	0.788	4.2	0.028	3.8	0.031	Leucine -rich alpha-2-glycoprotein 1	16418467	6.45	38154	124	16	5	3
29	1822.15 (1227.14)	1659.83 (905.35)	5152.16 (3376.72)	-1.1	0.781	2.8	0.029	3.1	0.023	Zinc-Alpha-2 Glycoprotein,	4699583	5.7	31626	266	51	17	4

(continued on next page)

Table 4 (continued)

Spot ID	Normalised spot volume – mean (SD)			Inter-group comparison – fold difference, unpaired t-test ($p < 0.05$)						Mass Spectrometry spectrometry data – MALDI-TOF/TOF							
	Oligo	Ext oligo	Poly	O vs EO	p	O vs P	p	EO vs P	p	Protein name	Accession number	pI	MW (KDa)	Mascot score	Sequence coverage	Matched peptides	Verification CID ions
30	2921.00 (2723.47)	2431.06 (956.73)	7297.04 (5067.90)	-1.2	0.599	2.5	0.026	3.0	0.033	Chain B Complement Component C3c, Chain C	78101271	4.79	39463	310	36	13	4
33	4.59 (4.69)	1.93 (1.70)	5.50 (2.28)	-2.4	0.116	1.2	0.620	2.9	0.008	Lipid-free Apolipoprotein A-I	90108664	5.27	28061	91	26	6	3
36	6000.68 (5893.61)	5767.56 (2843.52)	15,013.18 (10385.59)	-1.0	0.929	2.5	0.028	2.6	0.043	Hemopexin	11321561	6.55	51643	159	22	12	4
566	159.09 (245.58)	32.79 (18.65)	160.39 (136.42)	-4.9	0.121	1.0	0.989	4.9	0.035	Albumin, isoform CRA_k	119626074	5.97	47257	326	23	11	5
746	186.38 (238.51)	130.30 (67.38)	414.46 (319.46)	-1.4	0.480	2.2	0.092	3.2	0.044	Albumin, isoform CRA_p	119626064	8.42	25276	169	13	4	3
878	3545.92 (3336.53)	2008.83 (776.53)	4846.47 (2674.46)	-1.8	0.173	1.4	0.376	2.4	0.022	No Haptoglobin, isoform CRA_d	119579601	6.31	39944	301	38	17	5
907	15.51 (13.98)	15.43 (4.67)	35.12 (24.09)	-1.0	0.988	2.3	0.038	2.3	0.059	Leucine -rich alpha-2glycoprotein 1	16418467	6.45	38154	90	21	7	2
976	6907.62 (8543.54)	4224.08 (1702.29)	8598.26 (4362.93)	-1.6	0.336	1.2	0.616	2.0	0.040	Albumin, isoform CRA_g	119626070	5.66	22001	160	35	8	3
18	886.47 (935.84)	162.80 (123.00)	537.50 (382.84)	-5.4	0.030	-1.6	0.284	3.3	0.032	Immunoglobulin heavy chain variable region	39937967	5.13	16841	86	38	7	1
236	582.96 (1659.82)	36.57 (19.60)	93.55 (61.25)	-15.9	0.301	-6.2	0.352	2.6	0.039	No Identification	~	~	~	~	~	~	~
365	201.24 (265.85)	48.39 (53.68)	19.83 (15.50)	-4.2	0.093	-10.1	0.048	-2.4	0.262	Leucine -rich alpha-2-glycoprotein 1	16418467	6.45	38154	280	21	6	3
467	233.54 (236.91)	33.72 (38.09)	125.60 (199.55)	-6.9	0.021	-1.9	0.311	3.7	0.244	Albumin, isoform CRA_g	119626070	5.66	22001	376	35	9	6
542	399.12 (305.67)	134.22 (111.20)	707.90 (946.32)	-3.0	0.023	1.8	0.400	5.3	0.133	Immunoglobulin kappa 1 light chain	170684606	5.72	23238	177	40	6	3
663	312.00 (257.93)	79.96 (28.35)	220.35 (189.80)	-3.9	0.015	-1.4	0.408	2.8	0.078	No Identification	~	~	~	~	~	~	~
699	644.84 (497.06)	222.29 (72.19)	795.35 (983.82)	-2.9	0.020	1.2	0.666	3.6	0.145	Immunoglobulin light chain	149673887	6.97	233380	237	54	8	4
809	6.09 (4.56)	2.24 (0.63)	5.42 (4.21)	-2.7	0.021	-1.1	0.750	2.4	0.074	Albumin, isoform CRA_a	119626064	6.45	25276	57	13	4	1
836	1133.55 (937.82)	434.26 (340.27)	998.09 (882.61)	-2.6	0.045	-1.1	0.754	2.3	0.167	Chain A, Human Serum Transferrin, N-lobe	29726565	6.79	36533	649	41	16	9
865	1181.24 (706.11)	482.13 (350.29)	1189.55 (972.22)	-2.5	0.040	1.0	0.983	2.5	0.090	No Identification	~	~	~	~	~	~	~

Table 5 – Peptide ion validation data from CID MS/MS mass spectrometry which corresponds with Table 4.

Spot no.	Protein name	Accession number	Verification CID ions	Peptide position in protein sequence: start–end	m/z	Ions score	Amino acid sequence	Variable modification: carbamidomethyl cysteine (C), oxidation methionine (M)
20	Albumin, isoform CRA-t	119626083	2	162–168	927.5	21	K.YLYEIA.R	
				398–405	960.57	23	K.FQNALLV.R.Y	
26	Leucine -rich alpha-2-glycoprotein 1	16418467	2	165–175	1152.62	79	K.ALGHLDL.SG.N.R.L	
				251–260	989.56	83	R.VAAGAFQGL.R.Q	
27	HP protein	47124562	3	153–161	980.51	7	R.VGYVSGWGR.N	
				173–186	1707.82	30	K.YVMLPVADQDQ.CIR.H	C
				173–186	1723.81	41	K.YVMLPVADQDQ.CIR.H	C, M
32	Albumin, isoform CRA-k	119626074	3	169–180	1467.87	16	R.RHPDYSV.VLLLR.L	
				170–180	1311.76	12	R.RHPDYSV.VLLLR.L	
				235–242	960.59	56	K.FQNALLV.R.Y	
37	Apolipoprotein A-II isoform CRA_c	119573006	1	48–57	1156.69	75	K.SKEQLT.PLIK.K	
39	No identification	–	–					
41	Serum Albumin with S-Naproxen, Chain A	168988718	8	60–68	1017.55	39	K.SLHTLFGDK.L	
				89–101	1714.83	27	K.QEPERNECFLQHK.D	C
				133–139	927.52	36	K.YLYEIA.R	
				332–343	1467.87	26	R.RHPDYSV.VLLLR.L	
				333–343	1311.77	19	R.RHPDYSV.VLLLR.L	
				398–405	960.59	41	K.FQNALLV.R.Y	
				409–423	1639.97	27	K.KVPQVSTPTLVEVSR.N	
				410–423	1511.87	7	K.VPQVSTPTLVEVSR.N	
42	Apo-serum transferrin (non-glycosylated), Chain A	110590597	8	310–321	1478.72	44	K.MYLGYEYVTAIR.N	
				310–321	1494.71	30	K.MYLGYEYVTAIR.N	M
				341–349	1195.54	19	K.WCALSHHER.L	C
				509–519	1283.56	72	K.EGYGYTGAFR.C	
				555–565	1354.62	33	K.DYELLCLDGTR.K	C
				566–578	1586.76	41	R.KPVEEYANCHLAR.A	C
				625–637	1565.78	18	K.DLLFRDDTVCLAK.L	C
				662–674	1531.67	14	K.CSTSSLEACTFR.R	C
43	Vitamin D-binding protein/group specific component	455970	5	342–352	1388.69	50	K.VMDKYTFELSR.R	
				342–352	1404.68	36	K.VMDKYTFELSR.R	M
				346–352	915.47	22	K.YTFELSR.R	
				353–363	1326.76	38	R.RTHLPEVFLSK.V	
				354–363	1170.64	78	R.THLPEVFLSK.V	
694	Albumin, isoform CRA_h	119626071	3	427–434	960.57	8	K.FQNALLV.R.Y	
				438–452	1639.94	27	K.KVPQVSTPTLVEVSR.N	
				502–517	1910.93	17	R.RPCFSALEVDETYVPK.E	C
769	Albumin, isoform CRA_k	119626074	4	235–242	960.6	48	K.FQNALLV.R.Y	
				246–260	1639.99	72	K.KVPQVSTPTLVEVSR.N	
				247–260	1511.89	48	K.VPQVSTPTLVEVSR.N	
				317–332	1910.98	19	R.RPCFSALEVDETYVPK.E	C
770	No Identification	–	–					
872	HP Protein	47124562	3	153–161	980.5	65	R.VGYVSGWGR.N	
				173–186	1707.82	95	K.YVMLPVADQDQ.CIR.H	C
				173–186	1723.81	50	K.YVMLPVADQDQ.CIR.H	C, M
892	Albumin, isoform CRA_h	119626071	5	162–168	927.49	9	K.YLYEIA.R	
				427–434	960.56	35	K.FQNALLV.R.Y	
				438–452	1639.95	87	K.KVPQVSTPTLVEVSR.N	
				439–452	1511.85	40	K.VPQVSTPTLVEVSR.N	
				502–517	1910.94	14	R.RPCFSALEVDETYVPK.E	C
900	Haptoglobin	3337390	3	162–168	927.5	28	K.YLYEIA.R	
				427–434	960.56	41	K.FQNALLV.R.Y	
				438–452	1639.93	33	K.KVPQVSTPTLVEVSR.N	
904	Serum Albumin with S-Naproxen, Chain A	168988718	7	6–15	1226.61	65	R.FKDLGEENFK.A	
				60–68	1017.54	47	K.SLHTLFGDK.L	
				89–101	1714.8	20	K.QEPERNECFLQHK.D	
				132–139	1055.59	14	K.KYLYEIA.R	

(continued on next page)

Table 5 (continued)

Spot no.	Protein name	Accession number	Verification CID ions	Peptide position in protein sequence: start–end	m/z	Ions score	Amino acid sequence	Variable modification: carbamidomethyl cysteine (C), oxidation methionine (M)
5	Albumin, isoform CRA_h	119626071	4	133–139	927.51	57	K.YLYEIA.R	
				333–343	1311.75	21	R.HPDYSVVLRL.L	
				398–405	960.57	33	K.FQNALLV.R	
				162–168	927.5	28	K.YLYEIA.R	
				427–434	960.56	41	K.FQNALLV.R	
24	Haptoglobin	3337390	3	438–452	1639.93	33	K.KVPQVSTPTLVEVSR.N	
				502–517	1910.93	18	R.RPCFSALEVEDETYVPK.E	C
				217–225	980.52	61	R.VGYVSGWGR.N	
				237–250	1707.85	85	K.YVMLPVADQDQCIR.H	C
				237–250	1723.83	55	K.YVMLPVADQDQCIR.H	C, M
25	Leucine -rich alpha-2-glycoprotein 1	16418467	3	165–175	1152.64	50	K.ALGHLDLSGNR.L	
				210–216	812.48	18	R.GPLQLER.L	
				251–260	989.58	45	R.VAAGAFQGLR.Q	
29	Zinc-Alpha-2 Glycoprotein, Chain B	4699583	4	44–51	974.49	5	K.SQPMGLWR.Q	
				142–153	1532.79	82	K.QKWEAEPVYVQR.A	
				156–167	1451.68	56	K.AYLEEECPATLR.K	C
				211–217	926.49	24	K.IDVHWTR.A	
30	Complement Component C3c, Chain C	78101271	4	62–71	1250.63	41	K.NTMILEICTR.Y	C
				62–71	1266.61	11	K.NTMILEICTR.Y	C, M
				143–158	1841.98	120	K.VHQYFNVELIQPGAVK.V	
				159–171	1667.74	93	K.VYAYNLEESCTR.F	C
33	Lipid-free Apolipoprotein A-I	90108664	3	1–10	1226.57	34	DEPPQSPWDR.V	
				161–171	1301.66	22	R.THLAPYSDEL.R	
				207–215	1012.59	3	K.AKPALEDLR.Q	
36	Hemopexin	11321561	4	92–102	1220.61	64	K.NFPSPVDAAFR.Q	
				198–208	1495.68	20	R.YYCFQGNQFLR.F	
				209–219	1268.68	22	R.FDPVVRGEVPPR.Y	
				226–234	1142.49	21	R.DYFMPCPGR.G	
				269–280	1467.84	54	R.RHPDYSVVLRL.L	
566	Albumin, isoform CRA_k	119626074	5	170–180	1311.75	24	R.HPDYSVVLRL.L	
				235–242	960.57	43	K.FQNALLV.R	
				246–260	1639.94	103	K.KVPQVSTPTLVEVSR.N	
				247–260	1511.85	67	K.VPQVSTPTLVEVSR.N	
				100–115	1910.93	93	R.RPCFSALEVEDETYVPK.E	C
746	Albumin, isoform CRA_p	119626064	3	161–172	1342.62	45	K.AVMDDFAAFVEK.C	
				161–172	1358.62	64	K.AVMDDFAAFVEK.C	M
				126–133	920.46	51	K.GSFPWQAK.M	
878	No Haptoglobin, isoform CRA_d	119579601	5	233–241	980.5	77	R.VGYVSGWGR.N	
				253–266	1707.82	94	K.YVMLPVADQDQCIR.H	C
				253–266	1723.81	63	K.YVMLPVADQDQCIR.H	C, M
				347–356	1203.62	17	K.VTSIQDWVQK.T	
				165–175	1152.63	30	K.ALGHLDLSGNR.L	
907	Leucine -rich alpha-2glycoprotein 1	16418467	2	251–260	989.57	30	R.VAAGAFQGLR.Q	
				35–44	1226.59	47	R.FKDLGEEFK.A	
976	Albumin, isoform CRA_g	119626070	3	118–130	1714.79	14	K.QEPERNECFQHK.D	C
				162–168	927.5	29	K.YLYEIA.R	
				126–137	1287.67	55	K.GPSVFPLAPCSR.S	C
236	No Identification	–	–					
365	Leucine -rich alpha-2-glycoprotein 1	16418467	3	165–175	1152.62	57	K.ALGHLDLSGNR.L	
				192–209	2037.08	125	R.TLDLGENQLETLPDRLR.G	
				251–260	989.56	70	R.VAAGAFQGLR.Q	
467	Albumin, isoform CRA_g	119626070	6	35–44	1226.62	81	R.FKDLGEEFK.A	
				66–75	1149.62	59	K.LVNEVTEFAK.T	
				89–97	1017.54	57	K.SLHTLFGDK.L	
				118–130	1714.81	26	K.QEPERNECFQHK.D	C
				161–168	1055.6	23	K.KYLYEIA.R	
				162–168	927.51	42	K.YLYEIA.R	

Table 5 (continued)

Spot no.	Protein name	Accession number	Verification CID ions	Peptide position in protein sequence: start–end	m/z	Ions score	Amino acid sequence	Variable modification: carbamidomethyl cysteine (C), oxidation methionine (M)
542	Immunoglobulin kappa 1 light chain	170684606	3	46–61 109–126 191–207	1747.95 1946.04 1875.94	23 57 57	K.LLIYDASNLETGVPSR.F R.TVAAPSVFIFPPSDEQLK.S K.VYACEVTHQGLSSPVTK.S	C
663	No Identification	–	–					
699	Immunoglobulin light chain	149673887	4	1–18 47–55 63–78 128–143	1884.05 979.59 1632.82 1797.92	63 11 39 73	EIVLTQSPGTLISLSPGER.A R.LLIYGASSR.A R.FSGSGSGTDFLTISR.L K.SGTASVVCLLNNFYPR.E	C
809	Albumin, isoform CRA_a	119626064	1	162–168	927.51	24	K.YLYEIAR.R	
836	Chain A, Human Serum Transferrin, N-lobe	29726565	9	42–50 43–50 89–102 103–113 104–113 207–217 218–232 221–232 240–254	1125.59 997.49 1629.82 1323.66 1195.57 1273.65 1881.89 1539.73 1689.87	27 30 93 3 53 98 113 70 60	K.KASYLDCIR.A K.ASYLDCIR.A K.EDPQTFYYAVAVVK.K K.KDSGFQMNQLR.G K.DSGFQMNQLR.G K.HSTIFENLANK.A K.ADRDQYELLCLDNTR.K R.DQYELLCLDNTR.K K.DCHLAQVPSHTVVAR.S	C C C C C
865	No Identification	–	–					
875	No identification	–	–					
947	Chain A, Human Vitamin D Binding Protein	18655424	4	35–49 50–71 79–98 112–133	1694.9 2518.03 2264.94 2707.22	70 106 47 111	R.KFPGSGTFEQVSQLVK.E K.EVVSLTEACCAEGADPDCYDTR.T K.SCESNSPPVHPGTAECCTK.E K.HQPQEFPTYVEPTNDEICEAFR.K	 3C 3C C

Peptide position in the matched protein, observed mass (m/z) and amino acid sequence are listed for each protein match found.

shown that local and systemic disease can be differentiated by the clustering pattern of 52 proteins with consistent synovial or plasma 'specific' expression patterns. This discriminating group of proteins is expressed with at least twofold differences between the two sample types, but how relevant are these findings to the pathology of inflammatory arthritis in children. Fragments or precursors of anti-inflammatory proteins, endogenous protease inhibitors, albumin and complement factors have been identified among these.

A number of inhibitory acute phase proteins were associated with significant differences in local and systemic expression patterns. The levels of transthyretin, transferrin were raised in plasma whereas apolipoproteins (A-I, A-II and C-III) were conversely higher in synovial fluid. In rheumatoid arthritis patients, apolipoprotein A-I plasma levels are lower than normal controls [20,21], whereas in agreement with our findings the levels are increased in synovial fluid [22,23]. Apo A-I immunohistological staining is confined to perivascular areas within the synovium of RA patients [24]. It has been suggested that Apo A-I could inhibit the production of proinflammatory cytokine production [25] and may limit disease recurrence by inhibition of interactions between T lymphocytes and monocytes [26].

Investigation of the plasma from patients in the progressive stages of severe acute respiratory syndrome (SARS) revealed that apolipoprotein A-I, transthyretin and transferrin were at significantly lower levels than in normal controls and

convalescent patients [27]. These proteins belong to the negative acute phase proteins (APPs) and previous studies suggest that plasma concentrations decrease in response to inflammation because of increased rates of transcapillary escape degradation [28].

These proteins have also been identified at increased levels in the cerebrospinal fluid of Alzheimer disease patients where they are thought to function in plaque clearance [29]. It has been suggested that transient infiltration of negative APP plasma proteins may partially explain the relapse-remission cycles characteristic of JIA and other forms of inflammatory arthritis [24].

Raised levels of properdin, a component of the alternative complement activation pathway, were detected in synovial fluid. Properdin activates complement in the absence of immune complexes by stabilizing the C3 or C5 convertase complexes [30]. It is associated with the engulfing of foreign particles and invading cells by phagocytes and with tissue inflammation. As macrophages and T cells are able to secrete properdin into the synovial fluid, therefore these infiltrated cells are a likely source of the raised levels observed [31,32].

The increase in blood proteins may be a function of their metabolism within the joint, such that certain isoforms or fragments of a given protein may be detected at higher than anticipated levels. A concentration gradient may also contribute to raised amounts of select proteins due to the fluid pressure differential that exists between blood supplied to

the joint and the joint fluid itself [33]. A certain amount of 'leakiness' between the two fluids could be anticipated due to a breakdown in the integrity of the synovial capillary network, commonly observed in a range of rheumatic disorders as joint inflammation progresses [34]. The signal from a particular biomarker is likely to diminish with distance from the disease and in particular with dilution into the plasma.

The interpatient differences observed may be indicative of the dilution of a protein into the larger volume of plasma thus generating a narrower concentration interval and as previously eluded to, the heterogeneous degrees of joint inflammation which may result in a differential rates of protein turnover across the study patients.

Studies of capillary ultrafiltration and trans-synovial flow rates imply that macromolecular selectivity is a feature of the fenestrated membrane that separates synovial fluid and plasma. Synovial fluid formation is driven by a net imbalance in the pressures between capillary plasma and intra-articular fluid. Continuous drainage from and replenishment into the intra-articular space ensures the synovial fluid proteome remains in flux [33]. Although capillary ultrafiltrate is the base solution for synovial fluid, secretions are made by the local synovial lining cells. Size selectivity has been proposed on the theory that the hyaluronan lining the synovial space is able to filter proteins such as albumin by steric exclusion [35]. The rate of trans-synovial fluid loss and molecular sieving effects are determined by the chain length of hyaluronan concentrated at the synovial membrane surface [36]. Our observation of albumin isoforms at variable stages of degradation across synovial fluid and plasma may reflect molecular sieving between the synovial endothelium and the joint fluid or a differential rate of degradation between the two fluids.

Our study also showed a number of variable MWt / PI isoforms of the same albumin species with variable ratios between synovial fluid and plasma. This also suggests that same protein was subjected to variable post translational modifications, which may direct proportions of a single gene product to select locations relevant to disease pathology [37].

Inter alpha trypsin inhibitor and alpha 1 anti-trypsin were identified at higher synovial levels, compared to plasma which may represent the inherent anti-proteolytic character of normal synovial fluid. It is possible that these proteins are part of a homeostatic negative feedback system which protects the joint during inflammation. Inter alpha trypsin inhibitor and alpha 1 anti-trypsin were also detected alongside apolipoprotein, transferrin and transthyretin species in a recent 1DE-MS study of normal and osteoarthritic synovial fluids [38]. Support for our findings has been provided in a recent study of 500 peptide fragments from OA synovial fluid, which identified similar acute phase components apolipoprotein F precursor, inter- α inhibitor H4 and serum amyloid A [39]. Untargeted analysis of peptides was performed on synovial fluid from osteoarthritis patients in the liquid phase by reversed-phase nanoLC-MS. and it was suggested that peptide degradation products could reveal clinically relevant information on the activity of peptidases and proteases within the inflamed joint.

In the second study (group B) JIA patient subgroups, classified according to ILAR criteria, can be segregated in early disease based on the clustering patterns of 40 synovial fluid proteins. By extension of this finding, it may be possible to

differentiate JIA patients who suffer disease extension within the first year of diagnosis from the other disease subgroups tested. The discriminatory group of proteins is expressed with at least twofold differences between JIA patient subgroups, but how relevant are these findings to the pathology of inflammatory arthritis in children. Several acute-phase proteins, albumins, glycoproteins and immunoglobulins comprise this discriminatory subproteome. Substantial evidence suggests these molecules may govern a wide range of inflammatory pathways with relevance to the pathology of JIA.

A number of inhibitory acute phase proteins were associated with significant differences in JIA subgroup expression patterns. When compared to the synovial fluid proteome levels of the oligoarticular patient subgroup, apolipoprotein A-I was reduced in patients with extended oligoarticular disease, whereas apolipoprotein A-II was higher in the latter. Both apolipoprotein species were significantly higher in the polyarticular patients. In rheumatoid arthritis patients, apolipoprotein A-I levels are increased in synovial fluid [22,23]. It has been suggested that Apo A-I could inhibit the production of proinflammatory cytokine production [25] and may limit disease recurrence by inhibition of interactions between T lymphocytes and monocytes [26].

In line with apolipoprotein A-I levels, extended oligoarticular patients display a general trend towards reduced transferrin, haptoglobin and complement C3c relative to the other two patient subgroups. In support of the assertion that these relatively abundant host-response proteins could be involved in the spread of inflammation to previously unaffected joints, raised sera levels of these proteins have been recorded in breast cancer patients with metastatic relapse [40]. Furthermore, leucine rich alpha-2-glycoprotein identified in this study has been observed at elevated levels along with other acute phase protein in patients with severe acute respiratory syndrome [41]. Vitamin D binding proteins (VDBP) have been identified in synovial fluid at reduced levels to those found in plasma, reflecting its limited dialysis into the joint space [42]. Our synovial fluid analysis revealed significantly raised levels of VDBP in extended oligoarticular and polyarticular patient subgroups.

The samples used in this study were only taken at the time of initial knee inflammation, therefore are most relevant to the disease pathology in early disease. The data provided indicates that synovial fluid proteome profiles could be used to classify patients based on existing clinical definitions. By virtue of the definition of the extended oligoarticular patient subgroup (become polyarticular after 6 months of initial diagnosis) we consider that both prediction of disease evolution and subgroup discrimination are possible by the proposed protein biomarker panel. The ability to predict disease course would be a powerful tool in the limitation of adverse outcome such as disease extension, as it may flag such patients for more effective/aggressive treatment strategies at an earlier stage in the disease process than is currently possible. The authors consider the collection of samples at the earliest stage in the disease course an important feature of the current study and vital in the discovery of biomarkers which not only 'describe' the initial disease processes, but may also act as sentinels to predict subsequent disease outcome. By cataloguing the protein profiles and identities which best describe the joint status as disease progresses, it may also be possible

to monitor therapeutic response over time. Furthermore joint proteome records could help predict disease spread and joint damage. Considering the heterogeneity of patient outcome in JIA, therapeutic suppression of synovial joint inflammation, while neglecting the systemic components of chronic disease, may not represent the best possible way to manage non-responsive disease. Longer lasting remission could be possible by taking systemic sentinels into account.

The DIGE technique coupled with MALDI-TOF mass spectrometry limits biomarker detection to within an approximate dynamic range of 5 orders of magnitude. Alternate strategies will be used in future investigations to enrich less abundant proteins in body fluid samples (affinity depletion). Synovial fluid as a partial eluent of plasma is likely to mimic its protein concentration range over 10 orders of magnitude [15]. To reduce the dynamic range of the synovial fluid and enrich for lower abundance proteins, serum albumin and immunoglobulins could be removed by affinity depletion columns in future investigations [43]. Intact and partially degraded proteins or peptide fragments are more likely to leach into the circulating plasma [44]. Low molecular weight components could be enriched by size exclusion or reverse phase chromatography [45].

Protein expression patterns localized in the chronically inflamed joint may have the potential to identify patients more likely to suffer disease which spread to multiple joints. The differences noted are currently being validated with a larger independent patient cohort, where alternate methods of expression and functional analysis will be used to further corroborate the proteomic findings. The proteins identified could act as criteria to prevent disease extension to allow earlier, more aggressive therapeutic intervention.

Acknowledgements

We thank Janne Skaarup Crawford (Alphalyse A/S) for careful compilation of the supplemental MS data. This work has been supported by the Research and Development Office Northern Ireland Grant RRG 8.42 (to D.G. and M.R.).

REFERENCES

- [1] Symmons DP, Jones M, Osborne J, Sills J, Southwood TR, Woo P. Pediatric rheumatology in the united kingdom: data from the British pediatric rheumatology group national diagnostic register. *J Rheumatol* 1996;23:1975–80.
- [2] Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis: why does it vary so much? *J Rheumatol* 2002;29:1520–30.
- [3] Flato B, Sorskaar D, Vinje O, Lien G, Aasland A, Moum T, et al. Measuring disability in early juvenile rheumatoid arthritis: evaluation of a Norwegian version of the childhood health assessment questionnaire. *J Rheumatol* 1998;25:1851–8.
- [4] Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. *J Rheumatol* 2003;30:386–93.
- [5] Huemer C, Malleson PN, Cabral DA, Huemer M, Falger J, Zidek T, et al. Patterns of joint involvement at onset differentiate oligoarticular juvenile psoriatic arthritis from pauciarticular juvenile rheumatoid arthritis. *J Rheumatol* 2002;29:1531–5.
- [6] Hii CS, Marin LA, Halliday D, Robertson DM, Murray AW, Ferrante A. Regulation of human neutrophil-mediated cartilage proteoglycan degradation by phosphatidylinositol-3-kinase. *Immunology* 2001;102:59–66.
- [7] de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. *J Immunol* 2004;172:6435–43.
- [8] Khalkhali-Ellis Z, Seftor EA, Nieva DR, Seftor RE, Samaha HA, Bultman L, et al. Induction of invasive and degradative phenotype in normal synovial fibroblasts exposed to synovial fluid from patients with juvenile rheumatoid arthritis: role of mononuclear cell population. *J Rheumatol* 1997;24:2451–60.
- [9] Foell D, Frosch M, Schulze zur Wiesch A, Vogl T, Sorg C, Roth J. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? *Ann Rheum Dis* 2004;63:206–8.
- [10] Uhl M, Krauss M, Kern S, Herget G, Hauer MP, Althoefer C, et al. The knee joint in early juvenile idiopathic arthritis. *Acta Radiol* 2001;42:6–9.
- [11] Honkanen VE, Rautonen JK, Pelkonen PM. Intra-articular glucocorticoids in early juvenile chronic arthritis. *Acta Paediatr* 1993;82:1072–4.
- [12] Blelock S, McAllister C, Gibson D, Clarke S, Rooney M. Juvenile idiopathic arthritis: joint destruction vs joint repair. clinical and histological findings in early untreated disease. *Arthritis Rheum* 2006;54:S692.
- [13] Gibson DS, Blelock S, Brockbank S, Curry J, Healy A, McAllister C, et al. Proteomic analysis of recurrent joint inflammation in juvenile idiopathic arthritis. *J Proteome Res* 2006;5:1988–95.
- [14] Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. *Arthritis Rheum* 2003;48:2622–6.
- [15] Gibson DS, Rooney M. The human synovial fluid proteome: a key factor in the pathology of joint disease. *Proteomics Clin Appl* 2007;1:889–99.
- [16] Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. *Nat Biotechnol* 2006;24:971–83.
- [17] Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. *Nat Protoc* 2006;1:2856–60.
- [18] Pappin DJ, Hojrup P, Bleasby AJ. Rapid identification of proteins by peptide-mass fingerprinting. *Curr Biol* 1993;3:327–32.
- [19] Sinz A, Bantscheff M, Mikkat S, Ringel B, Drynda S, Kekow J, et al. Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. *Electrophoresis* 2002;23:3445–56.
- [20] Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, et al. Lipid profiles in untreated patients with rheumatoid arthritis. *J Rheumatol* 1999;26:1701–4.
- [21] Doherty NS, Littman BH, Reilly K, Swindell AC, Buss JM, Anderson NL. Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two-dimensional gel electrophoresis. *Electrophoresis* 1998;19:355–63.
- [22] Ananth L, Prete PE, Kashyap ML. Apolipoproteins A-I and B and cholesterol in synovial fluid of patients with rheumatoid arthritis. *Metabolism* 1993;42:803–6.
- [23] Busso N, Dudler J, Salvi R, Peclat V, Lenain V, Marcovina S, et al. Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints. *Am J Pathol* 2001;159:1445–53.
- [24] Bresnihan B, Gogarty M, FitzGerald O, Dayer JM, Burger D. Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? *Arthritis Res Ther* 2004;6:R563–6.
- [25] Hyka N, Dayer JM, Modoux C, Kohno T, Edwards III CK, Roux-Lombard P, et al. Apolipoprotein A-I inhibits the

- production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. *Blood* 2001;97:2381–9.
- [26] Burger D, Dayer JM. The role of human T-lymphocyte–monocyte contact in inflammation and tissue destruction. *Arthritis Res* 2002;4(Suppl 3):S169–76.
- [27] Wan J, Sun W, Li X, Ying W, Dai J, Kuai X, et al. Inflammation inhibitors were remarkably up-regulated in plasma of severe acute respiratory syndrome patients at progressive phase. *Proteomics* 2006;6:2886–94.
- [28] Mikkat S, Koy C, Ulbrich M, Ringel B, Glocker MO. Mass spectrometric protein structure characterization reveals cause of migration differences of haptoglobin alpha chains in two-dimensional gel electrophoresis. *Proteomics* 2004;4:3921–32.
- [29] Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. *Mol Cell Proteomics* 2005;4:2000–9.
- [30] Muller-Eberhard HJ, Schreiber RD. Molecular biology and chemistry of the alternative pathway of complement. *Adv Immunol* 1980;29:1–53.
- [31] Schwaeble W, Huemer HP, Most J, Dierich MP, Strobel M, Claus C, et al. Expression of properdin in human monocytes. *Eur J Biochem* 1994;219:759–64.
- [32] Wirthmuller U, Dewald B, Thelen M, Stover C, Schafer MK, Whaley K, et al. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. *J Immunol* 1997;158:4444–51.
- [33] Levick JR. A method for estimating macromolecular reflection by human synovium, using measurements of intra-articular half lives. *Ann Rheum Dis* 1998;57:339–44.
- [34] Gaffney K, Cookson J, Blades S, Coumbe A, Blake D. Quantitative assessment of the rheumatoid synovial microvascular bed by gadolinium-DTPA enhanced magnetic resonance imaging. *Ann Rheum Dis* 1998;57:152–7.
- [35] Levick JR, McDonald JN. Fluid movement across synovium in healthy joints: role of synovial fluid macromolecules. *Ann Rheum Dis* 1995;54:417–23.
- [36] Sabaratnam S, Arunan V, Coleman PJ, Mason RM, Levick JR. Size selectivity of hyaluronan molecular sieving by extracellular matrix in rabbit synovial joints. *J Physiol* 2005;567:569–81.
- [37] Oettl K, Stauber RE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. *Br J Pharmacol* 2007;151:580–90.
- [38] Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, et al. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. *Arthritis Res Ther* 2007;9:R36.
- [39] Kamphorst JJ, Heijden RV, Degroot J, Lafeber FP, Reijmers TH, El BV, et al. Profiling of endogenous peptides in human synovial fluid by NanoLC-MS: Method validation and peptide identification. *J Proteome Res* 2007;6:4388–96.
- [40] Goncalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M, et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. *Oncogene* 2006;25:981–9.
- [41] Chen JH, Chang YW, Yao CW, Chiueh TS, Huang SC, Chien KY, et al. Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. *Proc Natl Acad Sci U S A* 2004;101:17039–44.
- [42] Fairney A, Straffen AM, May C, Seifert MH. Vitamin D metabolites in synovial fluid. *Ann Rheum Dis* 1987;46:370–4.
- [43] Liao H, Wu J, Kuhn E, Chin W, Chang B, Jones MD, et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. *Arthritis Rheum* 2004;50:3792–803.
- [44] Thadikkaran L, Siegenthaler MA, Crettaz D, Queloz PA, Schneider P, Tissot JD. Recent advances in blood-related proteomics. *Proteomics* 2005;5:3019–34.
- [45] Glocker MO, Guthke R, Kekow J, Thiesen HJ. Rheumatoid arthritis, a complex multifactorial disease: on the way toward individualized medicine. *Med Res Rev* 2006;26:63–87.